|  |
| --- |
| June 15, 2021  Tim Lange  Head of Investor Relations Phone +49 201 177-3150  tim.lange@evonik.com |
|  |

Evonik Industries AG

Rellinghauser Straße 1-11

45128 Essen

Germany

Phone +49 201 177-01

Fax +49 201 177-3475

www.evonik.com

Supervisory Board  
Bernd Tönjes, Chairman  
Executive Board  
Christian Kullmann, Chairman  
Dr. Harald Schwager, Deputy Chairman  
Thomas Wessel, Ute Wolf

Registered Office is Essen

Register Court Essen Local Court

Commercial Registry B 19474

Evonik boosts its system solutions portfolio with the acquisition of the cosmetic delivery company Infinitec Activos

* Strong technological and strategic fit supports the portfolio shift of Evonik’s life science division Nutrition & Care towards system solutions
* Evonik enhances its capabilities to generate new concepts for scientifically substantiated consumer claims
* Evonik strengthens its existing active delivery business with seven additional proprietary delivery systems and enlarges its bio actives portfolio with several new natural-based active ingredients

**Essen, Germany.** Evonik has signed a purchase agreement to acquire the privately owned technology-driven company Infinitec Activos, with closing expected by July. The Spanish company focuses on the development and production of novel active delivery systems for cosmetic active ingredient applications. Infinitec Activos will be integrated into the Care Solutions business line of Evonik’s Nutrition & Care division complementing the active delivery systems acquired in 2017.

This latest acquisition continues the portfolio shift of Evonik’s life science division Nutrition & Care towards system solutions, which are characterized by high growth prospects and above average margin potential. Nutrition & Care aims to increase the share of system solutions it offers from 20 percent today, to more than 50 percent by 2030.

“Proven active delivery systems offer great opportunities to innovate new cosmetic ingredients with scientifically proven claims. This allows our personal care customers to differentiate,” said Yann d'Hervé, head of Evonik's Care Solutions business line.

With its portfolio of natural-based active ingredients and seven delivery systems, the integration of Infinitec Activos into the Care Solutions business line reinforces Evonik’s position as a sustainable specialties partner, while also further strengthening Nutrition & Care’s wide technology platform. By combining its existing actives portfolio with the new delivery systems, Care Solutions’ capabilities to generate new concepts for scientifically substantiated consumer cosmetic claims are significantly enhanced. The integration and roll-out across the existing platform of cosmetic solutions offers strong synergy potential

“We are convinced that the synergies created will not only bring benefits to our customers and both companies, but also create new opportunities across the entire personal care and beauty market value chain,” said Alfonso Hidalgo, Partner of Infinitec Activos S.L.

Infinitec Activos continues the strong acquisition track record of Nutrition & Care. Since 2016, the division has acquired ten companies with strong and complementary technology positions enhancing the entire product portfolio. Their successful integration has opened new markets, accelerated growth and created significant value.

The acquisition comprises 47 employees working at the company’s Barcelona Science Park head office, its manufacturing facility in Montornés del Vallès (Spain) and at its natural-based raw material producer, Naturethic. Founded in 2004, Infinitec Activos’ research and innovation focusses on building the next generation of cosmetic delivery systems with a highly qualified, science- and marketing-driven team. Customers include both small independent brands as well as global key accounts.

Infinitec Activos provides customers with individualised products. One example is its renowned, actively targeted, Cosmetic Drone proprietary technology, as well as its next-generation of PLGA (poly(lactic-co-glycolic acid))-based delivery system. The Company’s new generation of actively targeted delivery system decorates surface particles with two peptides for dual-mode cellular targeting, while its core has been loaded with the desired active ingredient. Evonik expects to leverage the intellectual property in adjacent markets such as Health Care where it has already deployed its liposomal delivery technology.

**Company information**

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

**Disclaimer**

In so far as forecasts or expectations are expressed in this IR news or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.